Federal officials have banned imports from another India-based drug manufacturing plant over quality control concerns.

The U.S. Food and Drug Administration's "import alert" on Mumbai-based Polydrug Laboratories Pvt Ltd's Ambernath manufacturing plant makes it the 10th site in the country this year to face such action, Fox News reports.

The move comes two months after Canada banned the same site, citing integrity issues. European nations have also barred imports from the plant since early June citing critical deficiencies.

Polydrug makes drugs to treat hypertension, fungal diseases, and muscle relaxants, and exports them to more than 70 countries across Europe, North America and Asia, according to its website.

The company did not immediately respond to a request seeking comment on Monday, after the FDA posted a notice of the ban on its website.

Several Indian drugmakers, including some of the country's largest, have faced FDA bans in the last few years over issues, as the FDA stepped up efforts to regulate the generic drugs industry.

The latest FDA action takes the total number of Indian drug manufacturing facilities that currently stand barred from exporting to the United States to 44 between 2011 and now, according to the FDA website.